img

Global Peptide Cancer Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Peptide Cancer Vaccine Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application

Cancer peptide vaccination, as an immunotherapeutic approach against solid tumors, is currently employed in several clinical research protocols. The underlying mechanism of peptide-based vaccines involves the generation of a T-cell immune response against tumor or enhancement of an endogenous antitumor immunity pre-existing in the host.
Peptide Cancer Vaccine report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Peptide Cancer Vaccine market is projected to reach US$ 1964.1 million in 2034, increasing from US$ 546.9 million in 2022, with the CAGR of 19.8% during the period of 2024 to 2034. Demand from Breast Cancer and Lung Cancer are the major drivers for the industry.
Peptide Cancer Vaccine can be used for Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer and Others cancers. The most proportion research of Peptide Cancer Vaccine is about Melanoma, and the proportion is about 40%.
USA is the largest consumption place, with a consumption market share nearly 53% . Following USA, Europe is the second largest consumption place with the consumption market share of 31%.
Boston Biomedical, Ultimovacs, BrightPath Biotherapeutics, TapImmune, Immatics, Sellas, Imugene, VAXON Biotech, Generex Biotechnology, ISA Pharmaceuticals and OncoTherapy Science are the key manufacturters of Peptide Cancer Vaccine.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Peptide Cancer Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Pipeline, Application and Regions Listed in the Report



By Company


Boston Biomedical
Ultimovacs
BrightPath Biotherapeutics
TapImmune
Immatics
Sellas
Imugene
VAXON Biotech
Generex Biotechnology
ISA Pharmaceuticals
OncoTherapy Science
Segment by Pipeline
ITK-1
GRN-1201
TPIV200
TPIV110
UV1
Galinpepimut-S
TARP 27-35
HER-Vaxx
Vx-001
Others

Segment by Application


Breast Cancer
Lung Cancer
Melanoma
Prostate Cancer
Others

Segment by Region


North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Peptide Cancer Vaccine market further
Chapter 1Product Definition, Product Pipelines, Volume and Revenue analysis of Each Pipeline in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Peptide Cancer Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Peptide Cancer Vaccine industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Peptide Cancer Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Peptide Cancer Vaccine introduction, etc. Peptide Cancer Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Peptide Cancer Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.

Table of Content

1 Peptide Cancer Vaccine Market Overview
1.1 Peptide Cancer Vaccine Product Overview
1.2 Peptide Cancer Vaccine Market Segment by Pipeline
1.2.1 ITK-1
1.2.2 GRN-1201
1.2.3 TPIV200
1.2.4 TPIV110
1.2.5 UV1
1.2.6 Galinpepimut-S
1.2.7 TARP 27-35
1.2.8 HER-Vaxx
1.2.9 Vx-001
1.2.10 Others
1.3 Global Peptide Cancer Vaccine Market Size by Pipeline
1.3.1 Global Peptide Cancer Vaccine Market Size Overview by Pipeline (2018-2034)
1.3.2 Global Peptide Cancer Vaccine Historic Market Size Review by Pipeline (2018-2024)
1.3.3 Global Peptide Cancer Vaccine Forecasted Market Size by Pipeline (2024-2034)
1.4 Key Regions Market Size Segment by Pipeline
1.4.1 North America Peptide Cancer Vaccine Sales Breakdown by Pipeline (2018-2024)
1.4.2 Europe Peptide Cancer Vaccine Sales Breakdown by Pipeline (2018-2024)
1.4.3 Asia-Pacific Peptide Cancer Vaccine Sales Breakdown by Pipeline (2018-2024)
1.4.4 Latin America Peptide Cancer Vaccine Sales Breakdown by Pipeline (2018-2024)
1.4.5 Middle East and Africa Peptide Cancer Vaccine Sales Breakdown by Pipeline (2018-2024)
2 Global Peptide Cancer Vaccine Market Competition by Company
2.1 Global Top Players by Peptide Cancer Vaccine Sales (2018-2024)
2.2 Global Top Players by Peptide Cancer Vaccine Revenue (2018-2024)
2.3 Global Top Players by Peptide Cancer Vaccine Price (2018-2024)
2.4 Global Top Manufacturers Peptide Cancer Vaccine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Peptide Cancer Vaccine Market Competitive Situation and Trends
2.5.1 Peptide Cancer Vaccine Market Concentration Rate (2018-2024)
2.5.2 Global 5 and 10 Largest Manufacturers by Peptide Cancer Vaccine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Peptide Cancer Vaccine as of 2022)
2.7 Date of Key Manufacturers Enter into Peptide Cancer Vaccine Market
2.8 Key Manufacturers Peptide Cancer Vaccine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Peptide Cancer Vaccine Status and Outlook by Region
3.1 Global Peptide Cancer Vaccine Market Size and CAGR by Region: 2018 VS 2022 VS 2034
3.2 Global Peptide Cancer Vaccine Historic Market Size by Region
3.2.1 Global Peptide Cancer Vaccine Sales in Volume by Region (2018-2024)
3.2.2 Global Peptide Cancer Vaccine Sales in Value by Region (2018-2024)
3.2.3 Global Peptide Cancer Vaccine Sales (Volume & Value) Price and Gross Margin (2018-2024)
3.3 Global Peptide Cancer Vaccine Forecasted Market Size by Region
3.3.1 Global Peptide Cancer Vaccine Sales in Volume by Region (2024-2034)
3.3.2 Global Peptide Cancer Vaccine Sales in Value by Region (2024-2034)
3.3.3 Global Peptide Cancer Vaccine Sales (Volume & Value), Price and Gross Margin (2024-2034)
4 Global Peptide Cancer Vaccine by Application
4.1 Peptide Cancer Vaccine Market Segment by Application
4.1.1 Breast Cancer
4.1.2 Lung Cancer
4.1.3 Melanoma
4.1.4 Prostate Cancer
4.1.5 Others
4.2 Global Peptide Cancer Vaccine Market Size by Application
4.2.1 Global Peptide Cancer Vaccine Market Size Overview by Application (2018-2034)
4.2.2 Global Peptide Cancer Vaccine Historic Market Size Review by Application (2018-2024)
4.2.3 Global Peptide Cancer Vaccine Forecasted Market Size by Application (2024-2034)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Peptide Cancer Vaccine Sales Breakdown by Application (2018-2024)
4.3.2 Europe Peptide Cancer Vaccine Sales Breakdown by Application (2018-2024)
4.3.3 Asia-Pacific Peptide Cancer Vaccine Sales Breakdown by Application (2018-2024)
4.3.4 Latin America Peptide Cancer Vaccine Sales Breakdown by Application (2018-2024)
4.3.5 Middle East and Africa Peptide Cancer Vaccine Sales Breakdown by Application (2018-2024)
5 North America Peptide Cancer Vaccine by Country
5.1 North America Peptide Cancer Vaccine Historic Market Size by Country
5.1.1 North America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
5.1.2 North America Peptide Cancer Vaccine Sales in Volume by Country (2018-2024)
5.1.3 North America Peptide Cancer Vaccine Sales in Value by Country (2018-2024)
5.2 North America Peptide Cancer Vaccine Forecasted Market Size by Country
5.2.1 North America Peptide Cancer Vaccine Sales in Volume by Country (2024-2034)
5.2.2 North America Peptide Cancer Vaccine Sales in Value by Country (2024-2034)
6 Europe Peptide Cancer Vaccine by Country
6.1 Europe Peptide Cancer Vaccine Historic Market Size by Country
6.1.1 Europe Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
6.1.2 Europe Peptide Cancer Vaccine Sales in Volume by Country (2018-2024)
6.1.3 Europe Peptide Cancer Vaccine Sales in Value by Country (2018-2024)
6.2 Europe Peptide Cancer Vaccine Forecasted Market Size by Country
6.2.1 Europe Peptide Cancer Vaccine Sales in Volume by Country (2024-2034)
6.2.2 Europe Peptide Cancer Vaccine Sales in Value by Country (2024-2034)
7 Asia-Pacific Peptide Cancer Vaccine by Region
7.1 Asia-Pacific Peptide Cancer Vaccine Historic Market Size by Region
7.1.1 Asia-Pacific Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
7.1.2 Asia-Pacific Peptide Cancer Vaccine Sales in Volume by Region (2018-2024)
7.1.3 Asia-Pacific Peptide Cancer Vaccine Sales in Value by Region (2018-2024)
7.2 Asia-Pacific Peptide Cancer Vaccine Forecasted Market Size by Region
7.2.1 Asia-Pacific Peptide Cancer Vaccine Sales in Volume by Region (2024-2034)
7.2.2 Asia-Pacific Peptide Cancer Vaccine Sales in Value by Region (2024-2034)
8 Latin America Peptide Cancer Vaccine by Country
8.1 Latin America Peptide Cancer Vaccine Historic Market Size by Country
8.1.1 Latin America Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
8.1.2 Latin America Peptide Cancer Vaccine Sales in Volume by Country (2018-2024)
8.1.3 Latin America Peptide Cancer Vaccine Sales in Value by Country (2018-2024)
8.2 Latin America Peptide Cancer Vaccine Forecasted Market Size by Country
8.2.1 Latin America Peptide Cancer Vaccine Sales in Volume by Country (2024-2034)
8.2.2 Latin America Peptide Cancer Vaccine Sales in Value by Country (2024-2034)
9 Middle East and Africa Peptide Cancer Vaccine by Country
9.1 Middle East and Africa Peptide Cancer Vaccine Historic Market Size by Country
9.1.1 Middle East and Africa Peptide Cancer Vaccine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2034
9.1.2 Middle East and Africa Peptide Cancer Vaccine Sales in Volume by Country (2018-2024)
9.1.3 Middle East and Africa Peptide Cancer Vaccine Sales in Value by Country (2018-2024)
9.2 Middle East and Africa Peptide Cancer Vaccine Forecasted Market Size by Country
9.2.1 Middle East and Africa Peptide Cancer Vaccine Sales in Volume by Country (2024-2034)
9.2.2 Middle East and Africa Peptide Cancer Vaccine Sales in Value by Country (2024-2034)
10 Company Profiles
10.1 Boston Biomedical
10.1.1 Boston Biomedical Company Information
10.1.2 Boston Biomedical Introduction and Business Overview
10.1.3 Boston Biomedical Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.1.4 Boston Biomedical Peptide Cancer Vaccine Products Offered
10.1.5 Boston Biomedical Recent Development
10.2 Ultimovacs
10.2.1 Ultimovacs Company Information
10.2.2 Ultimovacs Introduction and Business Overview
10.2.3 Ultimovacs Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.2.4 Ultimovacs Peptide Cancer Vaccine Products Offered
10.2.5 Ultimovacs Recent Development
10.3 BrightPath Biotherapeutics
10.3.1 BrightPath Biotherapeutics Company Information
10.3.2 BrightPath Biotherapeutics Introduction and Business Overview
10.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Products Offered
10.3.5 BrightPath Biotherapeutics Recent Development
10.4 TapImmune
10.4.1 TapImmune Company Information
10.4.2 TapImmune Introduction and Business Overview
10.4.3 TapImmune Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.4.4 TapImmune Peptide Cancer Vaccine Products Offered
10.4.5 TapImmune Recent Development
10.5 Immatics
10.5.1 Immatics Company Information
10.5.2 Immatics Introduction and Business Overview
10.5.3 Immatics Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.5.4 Immatics Peptide Cancer Vaccine Products Offered
10.5.5 Immatics Recent Development
10.6 Sellas
10.6.1 Sellas Company Information
10.6.2 Sellas Introduction and Business Overview
10.6.3 Sellas Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.6.4 Sellas Peptide Cancer Vaccine Products Offered
10.6.5 Sellas Recent Development
10.7 Imugene
10.7.1 Imugene Company Information
10.7.2 Imugene Introduction and Business Overview
10.7.3 Imugene Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.7.4 Imugene Peptide Cancer Vaccine Products Offered
10.7.5 Imugene Recent Development
10.8 VAXON Biotech
10.8.1 VAXON Biotech Company Information
10.8.2 VAXON Biotech Introduction and Business Overview
10.8.3 VAXON Biotech Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.8.4 VAXON Biotech Peptide Cancer Vaccine Products Offered
10.8.5 VAXON Biotech Recent Development
10.9 Generex Biotechnology
10.9.1 Generex Biotechnology Company Information
10.9.2 Generex Biotechnology Introduction and Business Overview
10.9.3 Generex Biotechnology Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.9.4 Generex Biotechnology Peptide Cancer Vaccine Products Offered
10.9.5 Generex Biotechnology Recent Development
10.10 ISA Pharmaceuticals
10.10.1 ISA Pharmaceuticals Company Information
10.10.2 ISA Pharmaceuticals Introduction and Business Overview
10.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Products Offered
10.10.5 ISA Pharmaceuticals Recent Development
10.11 OncoTherapy Science
10.11.1 OncoTherapy Science Company Information
10.11.2 OncoTherapy Science Introduction and Business Overview
10.11.3 OncoTherapy Science Peptide Cancer Vaccine Sales, Revenue and Gross Margin (2018-2024)
10.11.4 OncoTherapy Science Peptide Cancer Vaccine Products Offered
10.11.5 OncoTherapy Science Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Peptide Cancer Vaccine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Peptide Cancer Vaccine Industrial Chain Analysis
11.4 Peptide Cancer Vaccine Market Dynamics
11.4.1 Peptide Cancer Vaccine Industry Trends
11.4.2 Peptide Cancer Vaccine Market Drivers
11.4.3 Peptide Cancer Vaccine Market Challenges
11.4.4 Peptide Cancer Vaccine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Peptide Cancer Vaccine Distributors
12.3 Peptide Cancer Vaccine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

List of Figure

List of Tables
Table 1. Major Company of ITK-1
Table 2. Major Company of GRN-1201
Table 3. Major Company of TPIV200
Table 4. Major Company of TPIV110
Table 5. Major Company of UV1
Table 6. Major Company of Galinpepimut-S
Table 7. Major Company of TARP 27-35
Table 8. Major Company of HER-Vaxx
Table 9. Major Company of Vx-001
Table 10. Major Company of Others
Table 11. Global Peptide Cancer Vaccine Sales by Pipeline 2018 VS 2022 VS 2034 (US$ Million)
Table 12. Global Peptide Cancer Vaccine Sales by Pipeline (2018-2024) & (K Units)
Table 13. Global Peptide Cancer Vaccine Sales Market Share in Volume by Pipeline (2018-2024)
Table 14. Global Peptide Cancer Vaccine Sales by Pipeline (2018-2024) & (US& Million)
Table 15. Global Peptide Cancer Vaccine Market Share in Value by Pipeline (2018-2024)
Table 16. Global Peptide Cancer Vaccine Price by Pipeline (2018-2024) & (USD/Unit)
Table 17. Global Peptide Cancer Vaccine Sales by Pipeline (2024-2034) & (K Units)
Table 18. Global Peptide Cancer Vaccine Sales Market Share in Volume by Pipeline (2024-2034)
Table 19. Global Peptide Cancer Vaccine Sales by Pipeline (2024-2034) & (US$ Million)
Table 20. Global Peptide Cancer Vaccine Sales Market Share in Value by Pipeline (2024-2034)
Table 21. Global Peptide Cancer Vaccine Price by Pipeline (2024-2034) & (USD/Unit)
Table 22. North America Peptide Cancer Vaccine Sales by Pipeline (2018-2024) & (K Units)
Table 23. North America Peptide Cancer Vaccine Sales by Pipeline (2018-2024) & (US$ Million)
Table 24. Europe Peptide Cancer Vaccine Sales (K Units) by Pipeline (2018-2024)
Table 25. Europe Peptide Cancer Vaccine Sales by Pipeline (2018-2024) & (US$ Million)
Table 26. Asia-Pacific Peptide Cancer Vaccine Sales (K Units) by Pipeline (2018-2024)
Table 27. Asia-Pacific Peptide Cancer Vaccine Sales by Pipeline (2018-2024) & (US$ Million)
Table 28. Latin America Peptide Cancer Vaccine Sales (K Units) by Pipeline (2018-2024)
Table 29. Latin America Peptide Cancer Vaccine Sales by Pipeline (2018-2024) & (US$ Million)
Table 30. Middle East and Africa Peptide Cancer Vaccine Sales (K Units) by Pipeline (2018-2024)
Table 31. Middle East and Africa Peptide Cancer Vaccine Sales by Pipeline (2018-2024) & (US$ Million)
Table 32. Global Peptide Cancer Vaccine Sales by Company (2018-2024) & (K Units)
Table 33. Global Peptide Cancer Vaccine Sales Share by Company (2018-2024)
Table 34. Global Peptide Cancer Vaccine Revenue by Company (2018-2024) & (US$ Million)
Table 35. Global Peptide Cancer Vaccine Revenue Share by Company (2018-2024)
Table 36. Global Market Peptide Cancer Vaccine Price by Company (2018-2024) & (USD/Unit)
Table 37. Global Peptide Cancer Vaccine Top Manufacturers Manufacturing Base Distribution and Sales Area
Table 38. Global Peptide Cancer Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 39. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Peptide Cancer Vaccine as of 2022)
Table 40. Date of Key Manufacturers Enter into Peptide Cancer Vaccine Market
Table 41. Key Manufacturers Peptide Cancer Vaccine Product Type
Table 42. Mergers & Acquisitions, Expansion Plans
Table 43. Global Peptide Cancer Vaccine Market Size Comparison by Region (US$ Million): 2018 VS 2022 VS 2034
Table 44. Global Peptide Cancer Vaccine Sales by Region (2018-2024) & (K Units)
Table 45. Global Peptide Cancer Vaccine Sales Market Share in Volume by Region (2018-2024)
Table 46. Global Peptide Cancer Vaccine Sales by Region (2018-2024) & (US$ Million)
Table 47. Global Peptide Cancer Vaccine Sales Market Share in Value by Region (2018-2024)
Table 48. Global Peptide Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2024)
Table 49. Global Peptide Cancer Vaccine Sales by Region (2024-2034) & (K Units)
Table 50. Global Peptide Cancer Vaccine Sales Market Share in Volume by Region (2024-2034)
Table 51. Global Peptide Cancer Vaccine Sales by Region (2024-2034) & (US$ Million)
Table 52. Global Peptide Cancer Vaccine Sales Market Share in Value by Region (2024-2034)
Table 53. Global Peptide Cancer Vaccine Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2024-2034)
Table 54. Global Peptide Cancer Vaccine Sales by Application: 2018 VS 2022 VS 2034 (US$ Million)
Table 55. Global Peptide Cancer Vaccine Sales by Application (2018-2024) & (K Units)
Table 56. Global Peptide Cancer Vaccine Sales Market Share in Volume by Application (2018-2024)
Table 57. Global Peptide Cancer Vaccine Sales by Application (2018-2024) & (US$ Million)
Table 58. Global Peptide Cancer Vaccine Sales Market Share in Value by Application (2018-2024)
Table 59. Global Peptide Cancer Vaccine Price by Application (2018-2024) & (USD/Unit)
Table 60. Global Peptide Cancer Vaccine Sales by Application (2024-2034) & (K Units)
Table 61. Global Peptide Cancer Vaccine Sales Market Share in Volume by Application (2024-2034)
Table 62. Global Peptide Cancer Vaccine Sales by Application (2024-2034) & (US$ Million)
Table 63. Global Peptide Cancer Vaccine Sales Market Share in Value by Application (2024-2034)
Table 64. Global Peptide Cancer Vaccine Price by Application (2024-2034) & (USD/Unit)
Table 65. North America Peptide Cancer Vaccine Sales by Application (2018-2024) (K Units)
Table 66. North America Peptide Cancer Vaccine Sales by Application (2018-2024) & (US$ Million)
Table 67. Europe Peptide Cancer Vaccine Sales by Application (2018-2024) (K Units)
Table 68. Europe Peptide Cancer Vaccine Sales by Application (2018-2024) & (US$ Million)
Table 69. Asia-Pacific Peptide Cancer Vaccine Sales by Application (2018-2024) (K Units)
Table 70. Asia-Pacific Peptide Cancer Vaccine Sales by Application (2018-2024) & (US$ Million)
Table 71. Latin America Peptide Cancer Vaccine Sales by Application (2018-2024) (K Units)
Table 72. Latin America Peptide Cancer Vaccine Sales by Application (2018-2024) & (US$ Million)
Table 73. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2018-2024) (K Units)
Table 74. Middle East and Africa Peptide Cancer Vaccine Sales by Application (2018-2024) & (US$ Million)
Table 75. North America Peptide Cancer Vaccine Sales by Country (2018-2024) & (K Units)
Table 76. North America Peptide Cancer Vaccine Sales Market Share in Volume by Country (2018-2024)
Table 77. North America Peptide Cancer Vaccine Sales by Country (2018-2024) & (US$ Million)
Table 78. North America Peptide Cancer Vaccine Sales Market Share in Value by Country (2018-2024)
Table 79. North America Peptide Cancer Vaccine Sales by Country (2024-2034) & (K Units)
Table 80. North America Peptide Cancer Vaccine Sales Market Share in Volume by Country (2024-2034)
Table 81. North America Peptide Cancer Vaccine Sales by Country (2024-2034) & (US$ Million)
Table 82. North America Peptide Cancer Vaccine Sales Market Share in Value by Country (2024-2034)
Table 83. Europe Peptide Cancer Vaccine Sales by Country (2018-2024) & (K Units)
Table 84. Europe Peptide Cancer Vaccine Sales Market Share in Volume by Country (2018-2024)
Table 85. Europe Peptide Cancer Vaccine Sales by Country (2018-2024) & (US$ Million)
Table 86. Europe Peptide Cancer Vaccine Sales Market Share in Value by Country (2018-2024)
Table 87. Europe Peptide Cancer Vaccine Sales by Country (2024-2034) & (K Units)
Table 88. Europe Peptide Cancer Vaccine Sales Market Share in Volume by Country (2024-2034)
Table 89. Europe Peptide Cancer Vaccine Sales by Country (2024-2034) & (US$ Million)
Table 90. Europe Peptide Cancer Vaccine Sales Market Share in Value by Country (2024-2034)
Table 91. Asia-Pacific Peptide Cancer Vaccine Sales by Region (2018-2024) & (K Units)
Table 92. Asia-Pacific Peptide Cancer Vaccine Sales Market Share in Volume by Region (2018-2024)
Table 93. Asia-Pacific Peptide Cancer Vaccine Sales by Region (2018-2024) & (US$ Million)
Table 94. Asia-Pacific Peptide Cancer Vaccine Sales Market Share in Value by Region (2018-2024)
Table 95. Asia-Pacific Peptide Cancer Vaccine Sales by Region (2024-2034) & (K Units)
Table 96. Asia-Pacific Peptide Cancer Vaccine Sales Market Share in Volume by Region (2024-2034)
Table 97. Asia-Pacific Peptide Cancer Vaccine Sales by Region (2024-2034) & (US$ Million)
Table 98. Asia-Pacific Peptide Cancer Vaccine Sales Market Share in Value by Region (2024-2034)
Table 99. Latin America Peptide Cancer Vaccine Sales by Country (2018-2024) & (K Units)
Table 100. Latin America Peptide Cancer Vaccine Sales Market Share in Volume by Country (2018-2024)
Table 101. Latin America Peptide Cancer Vaccine Sales by Country (2018-2024) & (US$ Million)
Table 102. Latin America Peptide Cancer Vaccine Sales Market Share in Value by Country (2018-2024)
Table 103. Latin America Peptide Cancer Vaccine Sales by Country (2024-2034) & (K Units)
Table 104. Latin America Peptide Cancer Vaccine Sales Market Share in Volume by Country (2024-2034)
Table 105. Latin America Peptide Cancer Vaccine Sales by Country (2024-2034) & (US$ Million)
Table 106. Latin America Peptide Cancer Vaccine Sales Market Share in Value by Country (2024-2034)
Table 107. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2018-2024) & (K Units)
Table 108. Middle East and Africa Peptide Cancer Vaccine Sales Market Share in Volume by Country (2018-2024)
Table 109. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2018-2024) & (US$ Million)
Table 110. Middle East and Africa Peptide Cancer Vaccine Sales Market Share in Value by Country (2018-2024)
Table 111. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2024-2034) & (K Units)
Table 112. Middle East and Africa Peptide Cancer Vaccine Sales Market Share in Volume by Country (2024-2034)
Table 113. Middle East and Africa Peptide Cancer Vaccine Sales by Country (2024-2034) & (US$ Million)
Table 114. Middle East and Africa Peptide Cancer Vaccine Sales Market Share in Value by Country (2024-2034)
Table 115. Boston Biomedical Company Information
Table 116. Boston Biomedical Introduction and Business Overview
Table 117. Boston Biomedical Peptide Cancer Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 118. Boston Biomedical Peptide Cancer Vaccine Product
Table 119. Boston Biomedical Recent Development
Table 120. Ultimovacs Company Information
Table 121. Ultimovacs Introduction and Business Overview
Table 122. Ultimovacs Peptide Cancer Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 123. Ultimovacs Peptide Cancer Vaccine Product
Table 124. Ultimovacs Recent Development
Table 125. BrightPath Biotherapeutics Company Information
Table 126. BrightPath Biotherapeutics Introduction and Business Overview
Table 127. BrightPath Biotherapeutics Peptide Cancer Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 128. BrightPath Biotherapeutics Peptide Cancer Vaccine Product
Table 129. BrightPath Biotherapeutics Recent Development
Table 130. TapImmune Company Information
Table 131. TapImmune Introduction and Business Overview
Table 132. TapImmune Peptide Cancer Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 133. TapImmune Peptide Cancer Vaccine Product
Table 134. TapImmune Recent Development
Table 135. Immatics Company Information
Table 136. Immatics Introduction and Business Overview
Table 137. Immatics Peptide Cancer Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 138. Immatics Peptide Cancer Vaccine Product
Table 139. Immatics Recent Development
Table 140. Sellas Company Information
Table 141. Sellas Introduction and Business Overview
Table 142. Sellas Peptide Cancer Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 143. Sellas Peptide Cancer Vaccine Product
Table 144. Sellas Recent Development
Table 145. Imugene Company Information
Table 146. Imugene Introduction and Business Overview
Table 147. Imugene Peptide Cancer Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 148. Imugene Peptide Cancer Vaccine Product
Table 149. Imugene Recent Development
Table 150. VAXON Biotech Company Information
Table 151. VAXON Biotech Introduction and Business Overview
Table 152. VAXON Biotech Peptide Cancer Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 153. VAXON Biotech Peptide Cancer Vaccine Product
Table 154. VAXON Biotech Recent Development
Table 155. Generex Biotechnology Company Information
Table 156. Generex Biotechnology Introduction and Business Overview
Table 157. Generex Biotechnology Peptide Cancer Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 158. Generex Biotechnology Peptide Cancer Vaccine Product
Table 159. Generex Biotechnology Recent Development
Table 160. ISA Pharmaceuticals Company Information
Table 161. ISA Pharmaceuticals Introduction and Business Overview
Table 162. ISA Pharmaceuticals Peptide Cancer Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 163. ISA Pharmaceuticals Peptide Cancer Vaccine Product
Table 164. ISA Pharmaceuticals Recent Development
Table 165. OncoTherapy Science Company Information
Table 166. OncoTherapy Science Introduction and Business Overview
Table 167. OncoTherapy Science Peptide Cancer Vaccine Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2018-2024)
Table 168. OncoTherapy Science Peptide Cancer Vaccine Product
Table 169. OncoTherapy Science Recent Development
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Peptide Cancer Vaccine Market Trends
Table 173. Peptide Cancer Vaccine Market Drivers
Table 174. Peptide Cancer Vaccine Market Challenges
Table 175. Peptide Cancer Vaccine Market Restraints
Table 176. Peptide Cancer Vaccine Distributors List
Table 177. Peptide Cancer Vaccine Downstream Customers
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Peptide Cancer Vaccine Product Picture
Figure 2. Global Peptide Cancer Vaccine Market Size, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Peptide Cancer Vaccine Market Size Status and Outlook (2018-2034) & (US$ Million)
Figure 4. Global Peptide Cancer Vaccine Sales Status and Outlook (2018-2034) & (K Units)
Figure 5. Product Picture of ITK-1
Figure 6. Global ITK-1 Sales YoY Growth (2018-2034) & (K Units)
Figure 7. Product Picture of GRN-1201
Figure 8. Global GRN-1201 Sales YoY Growth (2018-2034) & (K Units)
Figure 9. Product Picture of TPIV200
Figure 10. Global TPIV200 Sales YoY Growth (2018-2034) & (K Units)
Figure 11. Product Picture of TPIV110
Figure 12. Global TPIV110 Sales YoY Growth (2018-2034) & (K Units)
Figure 13. Product Picture of UV1
Figure 14. Global UV1 Sales YoY Growth (2018-2034) & (K Units)
Figure 15. Product Picture of Galinpepimut-S
Figure 16. Global Galinpepimut-S Sales YoY Growth (2018-2034) & (K Units)
Figure 17. Product Picture of TARP 27-35
Figure 18. Global TARP 27-35 Sales YoY Growth (2018-2034) & (K Units)
Figure 19. Product Picture of HER-Vaxx
Figure 20. Global HER-Vaxx Sales YoY Growth (2018-2034) & (K Units)
Figure 21. Product Picture of Vx-001
Figure 22. Global Vx-001 Sales YoY Growth (2018-2034) & (K Units)
Figure 23. Product Picture of Others
Figure 24. Global Others Sales YoY Growth (2018-2034) & (K Units)
Figure 25. Global Peptide Cancer Vaccine Sales by Pipeline (2018-2034) & (US$ Million)
Figure 26. Global Peptide Cancer Vaccine Sales Market Share by Pipeline in 2022 & 2034
Figure 27. North America Peptide Cancer Vaccine Sales Market Share in Volume by Pipeline in 2022
Figure 28. North America Peptide Cancer Vaccine Sales Market Share in Value by Pipeline in 2022
Figure 29. Europe Peptide Cancer Vaccine Sales Market Share in Volume by Pipeline in 2022
Figure 30. Europe Peptide Cancer Vaccine Sales Market Share in Value by Pipeline in 2022
Figure 31. Asia-Pacific Peptide Cancer Vaccine Sales Market Share in Volume by Pipeline in 2022
Figure 32. Asia-Pacific Peptide Cancer Vaccine Sales Market Share in Value by Pipeline in 2022
Figure 33. Latin America Peptide Cancer Vaccine Sales Market Share in Volume by Pipeline in 2022
Figure 34. Latin America Peptide Cancer Vaccine Sales Market Share in Value by Pipeline in 2022
Figure 35. Middle East and Africa Peptide Cancer Vaccine Sales Market Share in Volume by Pipeline in 2022
Figure 36. Middle East and Africa Peptide Cancer Vaccine Sales Market Share in Value by Pipeline in 2022
Figure 37. The 5 and 10 Largest Manufacturers in the World: Market Share by Peptide Cancer Vaccine Sales in 2022
Figure 38. The 5 and 10 Largest Manufacturers in the World: Market Share by Peptide Cancer Vaccine Revenue in 2022
Figure 39. Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 40. Product Picture of Breast Cancer
Figure 41. Global Breast Cancer Sales YoY Growth (2018-2034) & (K Units)
Figure 42. Product Picture of Lung Cancer
Figure 43. Global Lung Cancer Sales YoY Growth (2018-2034) & (K Units)
Figure 44. Product Picture of Melanoma
Figure 45. Global Melanoma Sales YoY Growth (2018-2034) & (K Units)
Figure 46. Product Picture of Prostate Cancer
Figure 47. Global Prostate Cancer Sales YoY Growth (2018-2034) & (K Units)
Figure 48. Product Picture of Others
Figure 49. Global Others Sales YoY Growth (2018-2034) & (K Units)
Figure 50. Global Peptide Cancer Vaccine Sales by Application (2018-2034) & (US$ Million)
Figure 51. Global Peptide Cancer Vaccine Sales Market Share by Application in 2022 & 2034
Figure 52. North America Peptide Cancer Vaccine Sales Market Share in Volume by Application in 2022
Figure 53. North America Peptide Cancer Vaccine Sales Market Share in Value by Application in 2022
Figure 54. Europe Peptide Cancer Vaccine Sales Market Share in Volume by Application in 2022
Figure 55. Europe Peptide Cancer Vaccine Sales Market Share in Value by Application in 2022
Figure 56. Asia-Pacific Peptide Cancer Vaccine Sales Market Share in Volume by Application in 2022
Figure 57. Asia-Pacific Peptide Cancer Vaccine Sales Market Share in Value by Application in 2022
Figure 58. Latin America Peptide Cancer Vaccine Sales Market Share in Volume by Application in 2022
Figure 59. Latin America Peptide Cancer Vaccine Sales Market Share in Value by Application in 2022
Figure 60. Middle East and Africa Peptide Cancer Vaccine Sales Market Share in Value by Application in 2022
Figure 61. Key Raw Materials Price
Figure 62. Peptide Cancer Vaccine Manufacturing Cost Structure
Figure 63. Peptide Cancer Vaccine Industrial Chain Analysis
Figure 64. Channels of Distribution
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries